This inventor holds 2 USPTO granted patents. Top assignees: Meiji Seika Kabushiki Kaisha, Schering Aktiengesellschaft. Active years: 1991-1997.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Yokohama, JP (1991)
- Kanagawa, JP (1997)
Company Filing History:
Years Active: 1991-1997
Title: The Innovations of Taiichiro Imanishi
Introduction
Taiichiro Imanishi is a notable inventor based in Yokohama, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for dementia. With a total of two patents to his name, Imanishi's work has the potential to impact many lives.
Latest Patents
Imanishi's latest patents include innovative compounds such as antipsychotic benzoisothiazolyl piperazine derivatives. These compounds are designed to serve as anti-dementia drugs. The invention relates to a method of treating various forms of dementia, including cerebro-vascular dementia, Alzheimer's dementia, and dementia caused by brain tumors or cerebral trauma. The method involves administering rolipram, which has shown promise in addressing these complex conditions.
Career Highlights
Throughout his career, Taiichiro Imanishi has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Meiji Seika Kabushiki Kaisha and Schering Aktiengesellschaft. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Imanishi has collaborated with esteemed colleagues such as Yasuyuki Ichimaru and Yoshimasa Fukuda. These partnerships have likely enhanced his research and development efforts, leading to the successful creation of his patented inventions.
Conclusion
Taiichiro Imanishi's contributions to the field of pharmaceuticals, particularly in dementia treatment, highlight his innovative spirit and dedication to improving healthcare. His patents represent significant advancements that could benefit many individuals suffering from cognitive disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
